ROCKVILLE, MD / ACCESSWIRE / January 7, 2025 / Theralogix, a trusted leader in the nutritional supplement industry, proudly announces the launch of TheraCran® Max, a premium dual-action supplement designed to deliver daily urinary tract health support.* By combining content-certified cranberry extract with pure d-mannose, TheraCran Max provides a comprehensive, broad-spectrum approach to urinary health.*
TheraCran Max utilizes two scientifically backed ingredients that work in complementary ways. Each daily serving contains 40 mg of soluble proanthocyanidins (PACs) from the juice portion of a whole cranberry extract plus 1,000 mg of d-mannose. Cranberry PACs and d-mannose work in unique ways, both binding to bacteria to help flush it from the urinary tract.*
TheraCran Max is the only cranberry and d-mannose supplement independently tested and certified by NSF® International, ensuring content accuracy, purity, and safety. This rigorous third-party certification sets TheraCran Max apart in a market where assurance of quality and content accuracy are essential, but often absent.
As with all Theralogix products, TheraCran Max is manufactured in the USA in a GMP-compliant facility, spotlighting the company’s commitment to high-quality, evidence-based supplements. It is dye-free, gluten-free, and formulated specifically for anyone seeking reliable urinary tract health support.*
Theralogix is the #1 urologist-recommended supplement brand. When it comes to premium, research-backed nutritional supplements, Theralogix has set the standard for over two decades. TheraCran Max is now available for purchase on Theralogix.com and Amazon.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Contact Information
Shannon Mahon
smahon@theralogix.com
301.464.7210
SOURCE: Theralogix
View the original press release on accesswire.com
Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care…
SHEFFIELD, United Kingdom, Jan. 8, 2025 /PRNewswire/ -- BlackfinBio Ltd (BFB) a clinical stage gene therapy…
RANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced…
LONDON, UK / ACCESSWIRE / January 8, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased…
PhenQ is a natural weight management system that targets five major areas of metabolic health,…
Burlington, Ontario--(Newsfile Corp. - January 7, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT"…